Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
<h4>Background</h4>We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI).<h4>Patient...
Saved in:
| Main Authors: | Chih-Ning Cheng, Shang-Yi Huang, Pei-Wen Lien, Shih-Ting Huang, Fang-Ju Lin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0252124&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01) -
Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
by: Yan Wang, et al.
Published: (2025-02-01) -
Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01) -
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
by: Salomon Manier, et al.
Published: (2025-03-01) -
Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US
by: Niodita Gupta-Werner, et al.
Published: (2025-07-01)